Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
8.80
+0.02 (0.23%)
At close: Apr 28, 2026, 4:00 PM EDT
8.80
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:15 PM EDT
Rallybio Revenue
In the year 2025, Rallybio had annual revenue of $858.00K with 34.91% growth. Rallybio had revenue of $222.00K in the quarter ending December 31, 2025, with 484.21% growth.
Revenue (ttm)
$858.00K
Revenue Growth
+34.91%
P/S Ratio
55.41
Revenue / Employee
$61,286
Employees
14
Market Cap
46.39M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 43.77M |
| Cue Biopharma | 27.47M |
| Radiopharm Theranostics | 10.86M |
| Nutriband | 2.28M |
| Hyperion DeFi | 813.46K |
| Mereo BioPharma Group | 500.00K |
| Entera Bio | 42.00K |
RLYB News
- 2 months ago - Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga
- 2 months ago - Rallybio Transcript: M&A announcement - Transcripts
- 2 months ago - Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
- 2 months ago - Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
- 2 months ago - Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Business Wire
- 2 months ago - Rallybio Announces Reverse Stock Split of Common Stock - Business Wire
- 3 months ago - Rallybio Transcript: EGM 2026 - Transcripts
- 6 months ago - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire